Preoperative Systemic Chemotherapy Including Immune Checkpoint Inhibitors for Patients with Tumor-Associated Dermatomyositis
The administration of preoperative chemotherapy, including ICIs, to a patient with breast cancer and tumor-associated DM was found to be a safe and effective treatment approach. There is a need to better understand the interplay between ICIs and autoimmune diseases and to develop safe and effective treatment strategies for this unique patient population.
Authors
- Chikako Shimizu (ORCID: https://orcid.org/0000-0003-1448-5865)
- Yayoi Honda
- Akihiko Shimomura (ORCID: https://orcid.org/0000-0002-2557-8170)
- Hoshie Hirai
- Yukino Kawamura (ORCID: https://orcid.org/0000-0002-4708-8201)
- Tomoko Taniyama
- Dai Kitagawa (ORCID: https://orcid.org/0000-0002-9636-8488)
- Kazuki Hashimoto (ORCID: https://orcid.org/0000-0002-8324-2202)
- Hiroshi Kaneko (ORCID: https://orcid.org/0000-0002-7861-5086)
Institutions
- Juntendo University (JP)
- National Center for Global Health and Medicine (JP)
Publication Details
- Journal
- Case Reports in Oncology
- Published
- 2025-02-12
- DOI
- https://doi.org/10.1159/000543579
- Citations
- 1
- Primary Topic
- Inflammatory Myopathies and Dermatomyositis
- Type
- article
- Field-Weighted Citation Impact
- 1.35
Funders
- Pfizer
- AstraZeneca
- Eisai
- Chugai Pharmaceutical